IPM.ai, part of Real Chemistry (www.ipm.ai), transforms real world data into real world insights that uncover the ideal patient and their healthcare ecosystem so that life sciences companies can accelerate the commercialization of precision therapies for specialty and rare diseases that lead to optimal patient outcomes quicker, with less risk. IPM.ai’s Insights as a Service (IaaS) platform optimizes drug development, clinical study, product launch and commercial operations by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data universe of over 300 million de-identified patient journeys and 65 billion anonymized social determinants of health signals. We’re making the promise of precision medicine an analytical reality. And we’re just getting started.